Pay in 4 interest-free payments of $5.95 Learn more
Ships within 48 hours · Estimated delivery Sep 21 - Sep 26
Safety in patients with existing mild-moderate liver disease Correlation between weight loss and estimated liver fat reduction TRIUMPH-2 (Ongoing, Expected 2026) Primary Endpoints: Weight loss in diabetic patients HbA1c reduction Secondary Endpoints (Liver): Liver enzymes Metabolic markers Diabetic Population Note: Higher prevalence of MASLD/NASH (~40-50%), so liver benefits particularly important in this group
Overweight and obesity management | Guidance (NG246) - Medicines and surgery
This allows insulin to clear while preserving the anabolic window
But what exactly is happening in the body to create these benefits
While standard therapeutic doses have demonstrated cardiovascular and metabolic benefits in large clinical trials, the concept of using low dose GLP-1 for inflammation remains investigational, with no established FDA indication or standardized dosing protocols
